Qing Li

Potent and Preferential Degradation of CDK6 via PROteolysis TArgeting Chimera Degraders.

S. Chandarlapaty, H. Deng, Hongying Gao, 2019, Journal of medicinal chemistry.

Recurrent WWTR1 S89W mutations and Hippo pathway deregulation in clear cell carcinomas of the cervix

S. Chandarlapaty, J. Reis-Filho, B. Weigelt, 2022, The Journal of pathology.

HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway

Amanda R. Kulick, S. Chandarlapaty, J. Reis-Filho, 2021, Nature Communications.

KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function

Alessandro Pastore, Omar Abdel-Wahab, Young Rock Chung, 2018, Oncogene.

INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors

J. Chodera, S. Chandarlapaty, J. Reis-Filho, 2021, Cancer discovery.

Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.

Ronglai Shen, Jorge S. Reis-Filho, Nikolaus Schultz, 2018, Cancer cell.

Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion

S. Chandarlapaty, J. Reis-Filho, B. Weigelt, 2023, bioRxiv.

Somatic estrogen receptor α mutations that induce dimerization promote receptor activity and breast cancer proliferation

B. Katzenellenbogen, S. Chandarlapaty, J. Reis-Filho, 2023, The Journal of clinical investigation.